Focus on vaccine research and development! Baik Bio filed an IPO application on the Board.

On August 25th, the latest announcement of the Shanghai Stock Exchange's Science and Technology Board, Baike Bio filed an IPO application and was accepted.
sponsor is CITIC Securities Co., Ltd., with a proposed financing amount of 1.681 billion yuan.
according to the prospectus, the funds raised will be used primarily for research and development projects, as well as the production of three approved vaccine products, including chickenpox vaccine, rabies vaccine and freeze-dried nasal flu vaccine.
Screenshot Source: References: Three approved vaccines 1, chickenpox detoxifying live vaccine: chickenpox is an acute infectious disease caused by the initial infection of chickenpox-shingles virus, mainly in infants and preschool children.
2008 live vaccine for chickenpox detoxification, a sub-cortical injection that gives humans a vaccine.
according to the prospectus, the product is selected by the World Health Organization (WHO) recommended MRC-5 human secondary cells as production cells, and the WHO recommended chickenpox detoxification virus (Oka strain) as the production strain.
2, Human Rabies Vaccine (Vero Cells): Obtained a new drug certificate and drug registration approval in 2006, is a Vero cell rabies vaccine that is given to humans by intramuscular injection.
According to the prospectus, the product is prepared using rabies virus fixed virus (aG strain), using micro-carrier suspension culture, by ultrafiltration enrichment, inactivation, purification and production, after vaccination can stimulate the body to produce anti-rabies virus immunity.
3, freeze-dried nasal spray influenza detoxifying live vaccine: launched in 2020, suitable for people with flu susceptible during the flu season 3-17 years old, is a nasal spray to prevent influenza virus vaccine products.
According to the prospectus, the product uses the WHO recommended influenza virus re-matching and reduction strain prepared vaccine, through the nasal spray device to induce local mucosa immunity, neutral antibodies and cellular immunity to achieve the effect of preventing influenza virus.
in addition to the 14 products in the study pipeline (screenshot source: References, 1), 100 grams of biology also has 12 vaccines in the study and 2 all-human monoclonal antibodies in the study for the prevention and control of infectious diseases, 3 of which are in clinical trials and 11 are in preclinical research.
1, human rabies vaccine (Vero cell) freeze-dried dosage form: According to the prospectine, compared to liquid dosage form, the rabies vaccine freeze-dried dosage form is more stable, longer life, easier to transport and store.
products have been tested for safety and immunogenicity in Phase 3 clinical trials using randomized, double-blind methods.
phase 3 clinical trials have been largely completed and are expected to receive vaccine generation approvals by 2024.
2, shingles freeze-dried dosage form: clinical phase 3 is currently under way (completed), the product is expected to be approved for market in 2023.
, according to the prospecto, the product does not contain adages, product safety is better and product adverse reactions are less.
, as a freeze-dried dosage form, the expected product after the market transport and storage time has certain advantages.
3, bait-breaking vaccine (three-part) liquid dosage form: According to the prospectus, the product through the intramuscular injection group cell-free white-break joint vaccine, resulting in mucosa epithet cells and natural immune cells (such as macrophages and dexterous cells) on the subject recognition bacterial antigen caused a series of immune response activation, thereby inducing MHC-II class antigen-specific immune memory response response.
the product was noted for clinical trials in March this year and plans to start clinical trial site work in 2021.
references: The prospectines of Changchun Baike Biotech AG. Retrieved Nov. 27, 2019, in From.